Silence Therapeutics plc

www.silence-therapeutics.com

Silence Therapeutics is a leading RNA therapeutics company. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

ARGENX AND GENMAB ENTER PARTNERSHIP TO ADVANCE ANTIBODY THERAPIES IN IMMUNOLOGY AND ONCOLOGY

Globenewswire | April 18, 2023

news image

argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address ...

Read More

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

news image

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More

KD PHARMA GROUP AND HERBOLEA BIOTECH SIGN LICENSING AGREEMENT FOR USE OF BIO-HERBOLYSIS™ EXTRACTION TECHNOLOGY

KD Pharma Group | June 24, 2020

news image

The KD Pharma Group SA ("KD Pharma"), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl ("Herbolea"), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma the rights to utilize Herbolea's Bio-Herbolysis™ extraction technology in Europe.Bio-Herbolysis™ is a highly scalable, solven...

Read More

Cell and Gene Therapy, Medical

BE THE MATCH BIOTHERAPIES® INTRODUCES CIBMTR® CRO SERVICES

Be The Match BioTherapies® | January 18, 2023

news image

On January 17, 2023, Be The Match BioTherapies, a company that provides solutions for organizations that develop and commercialize cell and gene therapies, introduced its offering of CIBMTR® clinical research organization services (CRO services), which significantly reduces the time needed to launch and execute high-impact clinical trials. These CRO services are the outcome of a collaboration between Be The Match BioTherapies and CIBMTR, resulting in expertise and access to ...

Read More
news image

MedTech, Industrial Impact

ARGENX AND GENMAB ENTER PARTNERSHIP TO ADVANCE ANTIBODY THERAPIES IN IMMUNOLOGY AND ONCOLOGY

Globenewswire | April 18, 2023

argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address ...

Read More
news image

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More
news image

KD PHARMA GROUP AND HERBOLEA BIOTECH SIGN LICENSING AGREEMENT FOR USE OF BIO-HERBOLYSIS™ EXTRACTION TECHNOLOGY

KD Pharma Group | June 24, 2020

The KD Pharma Group SA ("KD Pharma"), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl ("Herbolea"), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma the rights to utilize Herbolea's Bio-Herbolysis™ extraction technology in Europe.Bio-Herbolysis™ is a highly scalable, solven...

Read More
news image

Cell and Gene Therapy, Medical

BE THE MATCH BIOTHERAPIES® INTRODUCES CIBMTR® CRO SERVICES

Be The Match BioTherapies® | January 18, 2023

On January 17, 2023, Be The Match BioTherapies, a company that provides solutions for organizations that develop and commercialize cell and gene therapies, introduced its offering of CIBMTR® clinical research organization services (CRO services), which significantly reduces the time needed to launch and execute high-impact clinical trials. These CRO services are the outcome of a collaboration between Be The Match BioTherapies and CIBMTR, resulting in expertise and access to ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us